QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Forecast, Price & News

$2.87
-0.05 (-1.71%)
(As of 06/9/2023 ET)
Compare
Today's Range
$2.83
$2.93
50-Day Range
$1.64
$3.21
52-Week Range
$1.60
$3.79
Volume
242,607 shs
Average Volume
643,376 shs
Market Capitalization
$496.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20

Autolus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
182.8% Upside
$8.20 Price Target
Short Interest
Healthy
0.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Autolus Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.88) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

103rd out of 986 stocks

Biological Products, Except Diagnostic Industry

12th out of 163 stocks


AUTL stock logo

About Autolus Therapeutics (NASDAQ:AUTL) Stock

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Stock News Headlines

Autolus Therapeutics (NASDAQ:AUTL) Shares Up 9%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Needham Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)
Where Autolus Therapeutics Stands With Analysts
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 7.5%
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update
The Latest Analyst Ratings for Autolus Therapeutics
Autolus Therapeutics (AUTL) Receives a Buy from Needham
See More Headlines

AUTL Price History

AUTL Company Calendar

Last Earnings
5/04/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
324
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.20
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+180.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-148,840,000.00
Pretax Margin
-2,328.35%

Debt

Sales & Book Value

Annual Sales
$6.36 million
Book Value
$1.73 per share

Miscellaneous

Free Float
128,595,000
Market Cap
$505.36 million
Optionable
Not Optionable
Beta
1.56

Key Executives

  • Christian Martin Itin
    Chief Executive Officer & Director
  • Christopher Vann
    Chief Operating Officer & Senior Vice President
  • Lucinda Crabtree
    Chief Financial Officer
  • Martin Pulé
    Chief Scientific Officer & Senior Vice President
  • David Brochu
    Chief Technical Officer & Senior Vice President













AUTL Stock - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price forecast for 2023?

5 brokerages have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 180.8% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2023?

Autolus Therapeutics' stock was trading at $1.90 at the start of the year. Since then, AUTL shares have increased by 53.7% and is now trading at $2.92.
View the best growth stocks for 2023 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 739,700 shares, a decline of 14.1% from the April 30th total of 861,000 shares. Based on an average trading volume of 573,600 shares, the short-interest ratio is presently 1.3 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) announced its earnings results on Thursday, May, 4th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The firm had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.09 million.

What ETFs hold Autolus Therapeutics' stock?

ETFs with the largest weight of Autolus Therapeutics (NASDAQ:AUTL) stock in their portfolio include Harbor Disruptive Innovation ETF (INNO).iShares Biotechnology ETF (IBB).

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (5.59%), Perpetual Ltd (1.07%), BlackRock Inc. (0.51%), JPMorgan Chase & Co. (0.25%), MAI Capital Management (0.25%) and ExodusPoint Capital Management LP (0.24%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $2.92.

How much money does Autolus Therapeutics make?

Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $505.36 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

The company employs 324 workers across the globe.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.

This page (NASDAQ:AUTL) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -